Meeting
2015 ASCO Annual Meeting
Efficacy of high-dose adjuvant interferon therapy in high-risk melanoma harboring gene mutations.
Authors
Xuan Wang
Peking University Cancer Hospital & Institute, Beijing, China
Xuan Wang , Li Li Mao , Lu Si , Zhihong Chi , Chuanliang Cui , Xi Nan Sheng , BIN LIAN , Bixia Tang , Xieqiao Yan , Jun Guo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma/Skin Cancers
Citation
J Clin Oncol 33, 2015 (suppl; abstr 9047)
DOI
10.1200/jco.2015.33.15_suppl.9047
Abstract #
9047
Poster Bd #
290
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Italian cohort of ipilimumab expanded access programme (EAP): Efficacy, safety, and correlation with mutation status in metastatic melanoma patients.
First Author: Paola Queirolo
Poster
2018 ASCO Annual Meeting
Dual MAPK inhibition (dMAPKi) as an effective therapeutic strategy for class II BRAF mutant (mt) metastatic melanoma (MM).
First Author: Matthew Dankner
Poster
2014 ASCO Annual Meeting
Droplet digital PCR monitoring of BRAF and NRAS plasma DNA as biomarkers of treatment response in stage IV melanoma.
First Author: David Polsky
First Author: Ines Esteves Domingues Pires Da Silva